[SCHEDULE 13G] Taysha Gene Therapies, Inc. SEC Filing

Rhea-AI Filing Summary

The Schedule 13G filed on 27 June 2025 discloses that The Goldman Sachs Group, Inc. and its affiliate Goldman Sachs & Co. LLC have acquired beneficial ownership of 12,748,968 shares of Taysha Gene Therapies, Inc. (TSHA) common stock. The position represents 5.1 % of TSHA’s outstanding shares, crossing the 5 % reporting threshold under Section 13(d) of the Securities Exchange Act.

All voting and dispositive authority over the shares is reported as shared; neither entity claims sole authority. The filing is on Schedule 13G, indicating a passive investment rather than an effort to influence control, as confirmed by the Item 10 certification.

Goldman Sachs & Co. LLC is classified as a broker-dealer, other organization, and investment adviser, while The Goldman Sachs Group, Inc. is identified as a holding company/control person. No additional group members or activist exhibits are included.

The disclosure confirms meaningful institutional ownership by a globally recognized financial institution, potentially improving share liquidity and lending credibility to TSHA. However, because it is a passive filing, it does not imply forthcoming strategic or operational changes at the issuer.

Positive

• Goldman Sachs entities disclose a 5.1 % (12.75 M shares) passive stake in TSHA, adding high-profile institutional ownership that can enhance liquidity and visibility.

Negative

• None.

Insights

Securities Analyst

TL;DR — Goldman Sachs now owns 5.1 % of TSHA, a passive but notable institutional stake with limited immediate strategic impact.

Materiality: Crossing the 5 % threshold triggers mandatory disclosure, so the market gains transparency into TSHA’s ownership structure. Goldman’s 12.75 M-share position is sizeable for a small-cap biotech, adding respected institutional support that may broaden analyst coverage and improve liquidity.

Intent: The 13G form and certification make clear the holding is passive; no activist agenda or control intent is signaled. Investors should not expect near-term governance or strategy pressure from Goldman.

Valuation Implications: Passive stakes rarely move intrinsic value, but they can narrow the discount associated with limited institutional following. Any price reaction is likely sentiment-driven rather than fundamental. Overall impact: mildly positive but not transformative.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

TAYSHA GENE THERAPIES, INC.

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

877619106

(CUSIP Number)

06/26/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 877619106

1

Names of Reporting Persons

THE GOLDMAN SACHS GROUP, INC.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 12,748,918.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 12,748,968.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

12,748,968.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP No. 877619106

1

Names of Reporting Persons

GOLDMAN SACHS & CO. LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 12,748,918.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 12,748,968.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

12,748,968.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

BD, OO, IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TAYSHA GENE THERAPIES, INC.
(b)	Address of issuer's principal executive offices: 3000 PEGASUS PARK DR STE 1430, DALLAS, X1, 75247
Item 2.
(a)	Name of person filing: THE GOLDMAN SACHS GROUP, INC.| GOLDMAN SACHS & CO. LLC
(b)	Address or principal business office or, if none, residence: The Goldman Sachs Group, Inc. 200 West Street New York, NY 10282| Goldman Sachs & Co. LLC 200 West Street New York, NY 10282
(c)	Citizenship: THE GOLDMAN SACHS GROUP, INC. - Delaware| GOLDMAN SACHS & CO. LLC - New York
(d)	Title of class of securities: Common Stock, par value $0.00001 per share
(e)	CUSIP No.: 877619106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: See the response(s)to Item 11 on the attached cover page(s).
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit (99.2)
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

THE GOLDMAN SACHS GROUP, INC.

Signature:	Name:Ameen Soetan
Name/Title:	Attorney-in-fact
Date:	06/27/2025

GOLDMAN SACHS & CO. LLC

Signature:	Name:Ameen Soetan
Name/Title:	Attorney-in-fact
Date:	06/27/2025

Exhibit Information

EXHIBIT (99.1) JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.00001 per share, of TAYSHA GENE THERAPIES, INC. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G. Date: 06/27/2025 THE GOLDMAN SACHS GROUP, INC. By:/s/ AMEEN SOETAN ---------------------------------------- Name: Ameen Soetan Title: Attorney-in-fact GOLDMAN SACHS & CO. LLC By:/s/ AMEEN SOETAN ---------------------------------------- Name: Ameen Soetan Title: Attorney-in-fact EXHIBIT (99.2) ITEM 7 INFORMATION ****Please update the footnotes here****

FAQ

What percentage of TSHA shares does Goldman Sachs now own?

5.1 % of the outstanding common stock as reported in the Schedule 13G.

How many TSHA shares are beneficially owned by Goldman Sachs?

The filing lists 12,748,968 shares under shared voting and dispositive power.

Does the Schedule 13G suggest activist intentions by Goldman Sachs?

No. The use of Schedule 13G and the Item 10 certification confirm a passive investment with no intent to influence control.

Why was a Schedule 13G filed instead of a Schedule 13D?

Because the stake is passive; Schedule 13D is required only when the investor seeks to influence or control the issuer.

When was the event that triggered the filing requirement?

The relevant event date is 26 June 2025 according to the cover page.

What is the CUSIP number for Taysha Gene Therapies common stock?

The CUSIP provided in the filing is 877619106.